We are live on ! Find out more
OVID icon

Ovid Therapeutics
OVID

62 hedge funds and large institutions have $110M invested in Ovid Therapeutics in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 22 increasing their positions, 17 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

29% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 17

1% more capital invested

Capital invested by funds: $109M → $110M (+$1.08M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.03% less ownership

Funds ownership: 49.96% → 49.92% (-0.03%)

7% less funds holding

Funds holding: 67 → 62 (-5)

42% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 12

Holders
62
Holders Change
-5
Holders Change %
-7.46%
% of All Funds
0.98%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
7
Increased
22
Reduced
17
Closed
12
Calls
$231K
Puts
–
Net Calls
+$231K
Net Calls Change
-$966K

Top Buyers

Rank Fund Capital Flow
1
CA
CHI Advisors
New York
+$1.42M
2
DCM
Driehaus Capital Management
Illinois
+$1.13M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$772K
4
BI
BVF Inc
California
+$692K
5
SCM
Stonepine Capital Management
Oregon
+$667K

Top Sellers

Rank Fund Capital Flow
1
PIM
Platinum Investment Management
Australia
-$2.46M
2
GC
Globeflex Capital
California
-$289K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$252K
4
AFM
Anson Funds Management
Texas
-$176K
5
B
Bailard
California
-$154K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$21.5M +$692K +220,000 +3%
EC
2
EcoR1 Capital
California
$19.2M +$111K +35,200 +0.6%
SCM
3
Stonepine Capital Management
Oregon
$13.2M +$667K +211,884 +5%
Vanguard Group
4
Vanguard Group
Pennsylvania
$11.6M +$772K +245,291 +7%
AG
5
Artal Group
Luxembourg
$7.85M – – –
Acadian Asset Management
6
Acadian Asset Management
Massachusetts
$6.71M +$312K +99,206 +5%
GC
7
Globeflex Capital
California
$4.1M -$289K -91,829 -7%
BlackRock
8
BlackRock
New York
$3.62M +$13.9K +4,430 +0.4%
D.E. Shaw & Co
9
D.E. Shaw & Co
New York
$2.79M +$408K +129,605 +17%
CA
10
CHI Advisors
New York
$2.68M +$1.42M +452,888 +113%
IC
11
Ikarian Capital
Texas
$2.32M +$105K +33,290 +5%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$1.55M -$252K -80,003 -14%
Millennium Management
13
Millennium Management
New York
$1.42M +$209K +66,299 +17%
Wells Fargo
14
Wells Fargo
California
$1.36M -$55.1K -17,514 -4%
BCM
15
Bridgeway Capital Management
Texas
$1.16M +$493K +156,700 +74%
DCM
16
Driehaus Capital Management
Illinois
$1.13M +$1.13M +359,976 New
Susquehanna International Group
17
Susquehanna International Group
Pennsylvania
$967K +$67.6K +21,504 +8%
Russell Investments Group
18
Russell Investments Group
United Kingdom
$865K -$96.2K -30,583 -10%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$726K -$66.6K -21,165 -8%
State Street
20
State Street
Massachusetts
$602K +$147K +46,884 +32%
DA
21
DCF Advisers
Connecticut
$445K – – –
SEI Investments
22
SEI Investments
Pennsylvania
$375K – – –
Fidelity Investments
23
Fidelity Investments
Massachusetts
$296K +$293K +93,213 +9,321%
Connor, Clark & Lunn Investment Management (CC&L)
24
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$273K -$103K -32,685 -27%
Renaissance Technologies
25
Renaissance Technologies
New York
$266K +$82.4K +26,200 +45%
1
2 3

OVID Hedge Fund Activity: Q1 2022 in Review

62 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q1 2022, worth a combined $110M — up 0.99% from $109M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of OVID and 7 opened new positions — a net loss of 5 holders — while 17 trimmed existing stakes and 22 added.

The largest buyer was CHI Advisors, adding an estimated $1.42M. The largest seller was Platinum Investment Management, exiting entirely with an estimated $2.46M sold.

  • 62 institutional investors held Ovid Therapeutics (OVID) as of Q1 2022, down from 67 in Q4 2021.
  • Funds reported $110M of Ovid Therapeutics stock for Q1 2022, up 0.99% quarter-over-quarter.
  • 7 funds opened new Ovid Therapeutics positions in Q1 2022 and 12 closed out, a net change of -5 holders.
  • The largest Ovid Therapeutics buyer in Q1 2022 was CHI Advisors, an estimated $1.42M added.
  • The largest Ovid Therapeutics seller in Q1 2022 was Platinum Investment Management, an estimated $2.46M sold.

Based on aggregated 13F filings for Q1 2022.